Anti-vascular endothelial growth factor treatment for retinal vein occlusions

Ophthalmologica

Volumn 227, Issue SUPPL. 1, 2012, Pages 30-35

  Campochiaro, Peter A ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Hypoxia; Macular edema; Retinal ischemia; Retinal vein occlusion; Vascular leakage

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ARTERY PERFUSION; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; DISEASE EXACERBATION; DISEASE SEVERITY; HUMAN; RECURRENT DISEASE; RETINA HEMORRHAGE; RETINA ISCHEMIA; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; TREATMENT OUTCOME; VISION; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; HUMANS; RECOMBINANT FUSION PROTEINS; RETINAL VEIN OCCLUSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84860174253     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000337157     Document Type: Article

References (21)

1. Klein R, Moss SE, Meuer SM, Klein BE: The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol 2008; 126: 513-518. (Pubitemid 351549845)
2. Green WR, Chan CC, Hutchins GM, Terry JM: Central vein occlusion: a prospective histological study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc 1981; 79: 371-421.
3. Hayreh SS: Occlusion of the central retinal vessels. Br J Ophthalmol 1965; 49: 626-645.
4. Eye Disease Case Control Study Group: Risk factors for branch retinal vein occlusion. Am J Ophthalmol 1993; 116: 286-296.
5. Weinberg D, Dodwell DG, Fern SA: Anatomy of arteriovenous crossings in branch retinal vein occlusion. Am J Ophthalmol 1990; 109: 298-302. (Pubitemid 20078949)
6. Zhao J, Sastry SM, Sperduto RD, Chew EY, Remaley NA: Arteriovenous crossing patterns in branch retinal vein occlusion: the Eye Disease Case-Control Study Group. Ophthalmology 1993; 100: 423-428. (Pubitemid 23088544)
7. Campochiaro PA: Retinal and choroidal neovascularization. J Cell Physiol 2000; 184: 301-310. (Pubitemid 30625492)
8. Campochiaro PA: Ocular neovascularisation and excessive vascular permeability. Expert Opin Biol Ther 2004; 4: 1395-1402. (Pubitemid 39222973)
9. Ozaki H, Hayashi H, Vinores SA, Moromizato Y, Campochiaro PA, Oshima K: Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res 1997; 64: 505-517. (Pubitemid 27321334)
10. Ferrara N, Damico L, Shams N, Lowman H, Kim R: Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26: 859-870. (Pubitemid 44547437)
11. Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV, Quinlan E, Zimmer-Galler I, Haller JA, Solomon S, Sung JU, Hadi Y, Janjua KA, Choy DF, Arron JR: Ranibizumab for macular edema due to retinal vein occlusions; implication of VEGF as a critical stimulator. Mol Ther 2008; 16: 791-799. (Pubitemid 351426182)
12. Pieramici DJ, Rabena M, Castellarin AA, Nasir M, See R, Norton T, Sanchez A, Risard S, Avery RL: Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology 2008; 115:e47-e54.
13. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, Freund KB, Klein R: Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009; 147: 298-306.
14. Brown DM, Campochiaro PA, Singh RP, Gray S, Rundle AC, Li Z, Rubio RG, Murahashi WY, Group CS: Efficacy and safety of ranibizumab in the treatment of macular edema secondary to central retinal vein occlusion: 6-month results of the phase III CRUISE study. Ophthalmology 2010; 117: 1124-1133.
15. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG, Group BS: Ranibizumab for macular edema following branch retinal vein occlusion: 6-month primary endpoint results of a phase III study. Ophthalmology 2010; 117: 1102-1112.
16. Campochiaro PA, Brown DM, Awh CC, Lee Y, Gray S, Saroj N, Murahashi WY, Rubio RG: Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118: 2041-2049.
17. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY: Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118: 1594-1602.
18. Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, Tolentino M, Gupta A, Duarte L, Madreperla S, Gonder J, Kapik B, Billman K, Kane FE, FAME Study Group: Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011; 118: 626-635.
19. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM Jr, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF: Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006; 26: 279-284. (Pubitemid 44318180)
20. Rabena MD, Pieramici DJ, Castellarin AA, Nair MA, Avery RL: Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007; 27: 419-425. (Pubitemid 46624280)
21. Stahl A, Agostini H, Lutz HL, Feltgen N: Bevacizumab in retinal vein occlusion - results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1429-1436. (Pubitemid 47423323)